Shihui Lai
Overview
Explore the profile of Shihui Lai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li X, Zhang Y, Li S, Shi J, Liu C, Li X, et al.
Hepatology
. 2024 Apr;
81(1):44-59.
PMID: 38683582
Background And Aims: HCC, particularly the multifocal HCC, features aggressive invasion and dismal prognosis. Locoregional treatments were often refractory to eliminate tumor tissue, resulting in residual tumor cells persisting and...
2.
Lin C, Li T, Wang Y, Lai S, Huang Y, Guo Z, et al.
Cell Death Dis
. 2023 Jul;
14(7):485.
PMID: 37524717
No abstract available.
3.
Zhou M, Na R, Lai S, Guo Y, Shi J, Nie J, et al.
Cytokine
. 2023 Jun;
169:156271.
PMID: 37331095
Biliary tract cancer (BTC) is a highly malignant tumor that originates from bile duct epithelium and is categorized into intrahepatic cholangiocarcinoma (iCCA), perihilar cholangiocarcinoma (pCCA), distal cholangiocarcinoma (dCCA) and gallbladder...
4.
Lin C, Li T, Wang Y, Lai S, Huang Y, Guo Z, et al.
Cell Death Dis
. 2023 Mar;
14(3):221.
PMID: 36977668
The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling...
5.
Jia G, Wang Y, Lin C, Lai S, Dai H, Wang Z, et al.
J Exp Clin Cancer Res
. 2023 Mar;
42(1):54.
PMID: 36864449
No abstract available.
6.
Lin C, Wang Y, Dong Y, Lai S, Wang L, Weng S, et al.
Biol Direct
. 2022 Nov;
17(1):33.
PMID: 36397058
Background: Pancreatic cancer (PC) is highly malignant. Chemotherapy is the main treatment strategy, especially for patients with advanced PC. However, chemoresistance has always been a frequently encountered bottleneck. Hence, there...
7.
Zhao L, Su H, Liu X, Wang H, Feng Y, Wang Y, et al.
Cell Biosci
. 2022 Nov;
12(1):183.
PMID: 36371321
Background: Exploiting cancer metabolism during nutrient availability holds immense potential for the clinical and therapeutic benefits of hepatocellular carcinoma (HCC) patients. Dietary methionine is a metabolic dependence of cancer development,...
8.
Wang H, Wang Y, Lai S, Zhao L, Liu W, Liu S, et al.
Cell Death Discov
. 2022 Nov;
8(1):449.
PMID: 36344496
Accumulating evidence suggests that long noncoding RNAs (lncRNAs) are deregulated in hepatocellular carcinoma (HCC) and play a role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, the current...
9.
Zhang Y, Liu X, Wang Y, Lai S, Wang Z, Yang Y, et al.
Mol Cancer
. 2022 Sep;
21(1):174.
PMID: 36056355
Background: Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and...
10.
Lai S, Wang Y, Li T, Dong Y, Lin Y, Wang L, et al.
Cell Biosci
. 2022 Aug;
12(1):125.
PMID: 35941702
Background: Alternative splicing (AS) of genes has been found to affect gene stability, and its abnormal regulation can lead to tumorigenesis. CELF2 is a vital splicing factor to participate in...